These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 21364581)
1. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Sheng Q; Liu J Br J Cancer; 2011 Apr; 104(8):1241-5. PubMed ID: 21364581 [TBL] [Abstract][Full Text] [Related]
3. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer. Gui T; Shen K Cancer Epidemiol; 2012 Oct; 36(5):490-6. PubMed ID: 22818908 [TBL] [Abstract][Full Text] [Related]
4. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells. Choi BK; Fan X; Deng H; Zhang N; An Z Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251 [TBL] [Abstract][Full Text] [Related]
5. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer. Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079 [TBL] [Abstract][Full Text] [Related]
6. Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging. Macdonald-Obermann JL; Adak S; Landgraf R; Piwnica-Worms D; Pike LJ J Biol Chem; 2013 Oct; 288(42):30773-30784. PubMed ID: 24014028 [TBL] [Abstract][Full Text] [Related]
7. ErbB receptor tyrosine kinase inhibitors as therapeutic agents. Anderson NG; Ahmad T Front Biosci; 2002 Sep; 7():d1926-40. PubMed ID: 12161338 [TBL] [Abstract][Full Text] [Related]
8. Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells. Lammering G; Lin PS; Contessa JN; Hampton JL; Valerie K; Schmidt-Ullrich RK Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):775-84. PubMed ID: 11697324 [TBL] [Abstract][Full Text] [Related]
9. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion. Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194 [TBL] [Abstract][Full Text] [Related]
10. Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology. Pellat A; Vaquero J; Fouassier L Hepatology; 2018 Feb; 67(2):762-773. PubMed ID: 28671339 [TBL] [Abstract][Full Text] [Related]
11. The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways. Kovacevic Z; Menezes SV; Sahni S; Kalinowski DS; Bae DH; Lane DJ; Richardson DR J Biol Chem; 2016 Jan; 291(3):1029-52. PubMed ID: 26534963 [TBL] [Abstract][Full Text] [Related]
12. Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer. Zhang P; Zhang P; Zhou M; Jiang H; Zhang H; Shi B; Pan X; Gao H; Sun H; Li Z Carcinogenesis; 2013 Nov; 34(11):2639-46. PubMed ID: 23764753 [TBL] [Abstract][Full Text] [Related]
13. Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer. Alberti C; Pinciroli P; Valeri B; Ferri R; Ditto A; Umezawa K; Sensi M; Canevari S; Tomassetti A Oncogene; 2012 Sep; 31(37):4139-49. PubMed ID: 22158046 [TBL] [Abstract][Full Text] [Related]
14. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232 [TBL] [Abstract][Full Text] [Related]
15. Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs. Reddy TP; Choi DS; Anselme AC; Qian W; Chen W; Lantto J; Horak ID; Kragh M; Chang JC; Rosato RR Breast Cancer Res; 2020 May; 22(1):48. PubMed ID: 32414394 [TBL] [Abstract][Full Text] [Related]
18. A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy. Claus J; Patel G; Ng T; Parker PJ Biochem Soc Trans; 2014 Aug; 42(4):831-6. PubMed ID: 25109965 [TBL] [Abstract][Full Text] [Related]
19. [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma]. Li MJ; Li HR; Cheng X; Bi R; Tu XY; Liu F; Chen LH Zhonghua Fu Chan Ke Za Zhi; 2017 Dec; 52(12):835-843. PubMed ID: 29325268 [No Abstract] [Full Text] [Related]
20. ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas. Song X; Fan PD; Bantikassegn A; Guha U; Threadgill DW; Varmus H; Politi K Cancer Res; 2015 Mar; 75(6):1035-45. PubMed ID: 25596284 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]